FORE Biotherapeutics
Financing Round
- Series D+
Round Led or Co-led By SymBiosis
FORE Biotherapeutics is developing targeted therapies for patients with hard-to-treat cancers. Its lead candidate, plixorafenib, is a first-in-class BRAF inhibitor designed to target both V600 and non-V600 BRAF alterations and intended to address limitations of earlier-generation BRAF therapies. The company is evaluating plixorafenib in its global FORTE basket study across multiple BRAF-altered tumor types.
